peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Addressing urgent unmet needs in rare diseases

At Hansa Biopharma, we are on a mission to develop innovative immunomodulatory treatments and bring them to those patients whose medical needs have been overlooked.

This is Hansa

One enzyme platform, many therapeutic opportunities

Our unique enzyme technology platform can transform the lives of people affected by rare immunologic conditions, by advancing scientific innovation in many disease areas.

Our technology platform

Empowering patients with innovative therapies

We are dedicated to developing lifesaving and life altering treatments that can empower patients affected by rare immunologic conditions to live longer and healthier lives.

Therapeutic areas

    “We are leveraging our cutting-edge science to develop lifesaving and life altering therapies for patients with rare immunological conditions.”

    Søren Tulstrup, President and CEO


    Years of innovation


    Clinical and preclinical programs


    Nationalities represented in our workforce

    Annual Report 2023
    Sustainability Report 2023

    Addressing unmet need in rare diseases

    Read the reports


    Our latest press releases

    Our Technology platform

    Our unique antibody-cleaving enzyme technology

    We have developed our proprietary antibody-cleaving enzyme technology platform to target pathogenic or disease causing antibodies. Our first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate IgG antibodies in the plasma and tissue through a single intravenous treatment. We are currently investigating the use of this molecule for treating and preventing rare conditions caused by IgG antibodies in the acute phase, within transplantation, autoimmunity, gene therapy and oncology.

    Our technology platform


    News and insights

    Therapeutic Areas

    Our unique enzyme technology has the potential to transform the lives of people affected by rare immunologic conditions, including transplant rejection, genetic diseases, autoimmune conditions, and cancer.

    Melissa. Highly sensitized kidney patient on dialysis, USA.


    We are the bigger picture

    Since 2007, we have been fully committed to those living with rare conditions and have worked to develop lifesaving and life altering therapies through pioneering research and innovation. We strive to live up to the high ethical standards we set for ourselves, and to be a force for good both for individuals and society as a whole.

    Our commitment

    A truly great place to work

    Our strong company culture is what led us to be awarded Great Place to Work for four consecutive years from 2020 to 2023, by the independent institute Great Place to Work®, a global authority on workplace culture, employee experience and leadership behavior. In addition, Hansa has been selected among the best workplaces in Sweden in 2023.

    Strategic Partnerships

    We partner to maximize the impact of our technology on patients’ lives

    We value collaboration with strategic partners as an important part in our mission to develop innovative treatments that can address the unmet needs of rare disease patients and we seek the best partnering opportunities to maximize the potential of our technology platform. Our technology has received external validation through multiple collaborations, and it could potentially be used in a variety of transplantation and autoimmune indications, and as a pre-treatment ahead of gene therapy.


    Ready for a new career? Join us

    Coffee and notepad


    Sign up to receive updates on the latest company news and filings

    Choose type

    I consent to Hansa Biopharma handling my personal data. See our Privacy Policy for information about how we handle personal data.

    Thank you. You will get an e-mail message to activate your subscription.